Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Conformis stock | 0.663

Own Conformis stock in just a few minutes.

Posted

Fact checked

Conformis, Inc is a medical devices business based in the US. Conformis shares (CFMS) are listed on the NASDAQ and all prices are listed in US Dollars. Conformis employs 262 staff and has a trailing 12-month revenue of around USD$73.1 million.

How to buy shares in Conformis

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Conformis. Find the stock by name or ticker symbol: CFMS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Conformis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.663, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Conformis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Conformis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Conformis's share price?

Since the stock market crash in March caused by coronavirus, Conformis's share price has had significant negative movement.

Its last market close was USD$0.663, which is 36.86% down on its pre-crash value of USD$1.05 and 32.52% up on the lowest point reached during the March crash when the shares fell as low as USD$0.5003.

If you had bought USD$1,000 worth of Conformis shares at the start of February 2020, those shares would have been worth USD$637.14 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$670.51.

Conformis share price

Use our graph to track the performance of CFMS stocks over time.

Conformis shares at a glance

Information last updated 2020-10-20.
Latest market close USD$0.663
52-week range USD$0.5003 - USD$2.39
50-day moving average USD$0.7774
200-day moving average USD$0.7992
Wall St. target price USD$2.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.515

Buy Conformis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Conformis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Conformis price performance over time

Historical closes compared with the close of $0.663 from 2020-11-16

1 week (2020-11-19) 4.74%
1 month (2020-10-27) -3.91%
3 months (2020-08-26) -0.45%
6 months (2020-05-26) -32.48%
1 year (2019-11-26) -64.73%
2 years (2018-11-26) 30.26%
3 years (2017-11-24) -79.66%
5 years (2015-11-25) -96.82%

Is Conformis under- or over-valued?

Valuing Conformis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Conformis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Conformis's PEG ratio

Conformis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.21. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Conformis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Conformis financials

Revenue TTM USD$73.1 million
Gross profit TTM USD$36.7 million
Return on assets TTM -21.43%
Return on equity TTM -143.36%
Profit margin -35.03%
Book value $0.111
Market capitalisation USD$60.9 million

TTM: trailing 12 months

Shorting Conformis shares

There are currently 577,497 Conformis shares held short by investors – that's known as Conformis's "short interest". This figure is 28% down from 802,537 last month.

There are a few different ways that this level of interest in shorting Conformis shares can be evaluated.

Conformis's "short interest ratio" (SIR)

Conformis's "short interest ratio" (SIR) is the quantity of Conformis shares currently shorted divided by the average quantity of Conformis shares traded daily (recently around 497842.24137931). Conformis's SIR currently stands at 1.16. In other words for every 100,000 Conformis shares traded daily on the market, roughly 1160 shares are currently held short.

However Conformis's short interest can also be evaluated against the total number of Conformis shares, or, against the total number of tradable Conformis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Conformis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Conformis shares in existence, roughly 10 shares are currently held short) or 0.0076% of the tradable shares (for every 100,000 tradable Conformis shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Conformis.

Find out more about how you can short Conformis stock.

Conformis share dividends

We're not expecting Conformis to pay a dividend over the next 12 months.

Conformis share price volatility

Over the last 12 months, Conformis's shares have ranged in value from as little as $0.5003 up to $2.39. A popular way to gauge a stock's volatility is its "beta".

CFMS.US volatility(beta: 1.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Conformis's is 1.7981. This would suggest that Conformis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Conformis overview

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia. Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site